Semax
Research OnlyAlso known as: ACTH(4-7)PGP, Methionyl-Glutamyl-Histidyl-Phenylalanyl-Prolyl-Glycyl-Proline, MEHFPGP
A synthetic heptapeptide analogue of ACTH(4-7) with a C-terminal Pro-Gly-Pro extension, developed by Russian researchers and approved in Russia since ~1997 for stroke, cognitive impairment, and optic nerve disorders. Demonstrates nootropic and neuroprotective effects through BDNF/NGF upregulation, dopaminergic and serotonergic modulation, and anti-inflammatory mechanisms. Extensive Russian clinical research supports efficacy, particularly in stroke rehabilitation, though Western independent replication remains limited.
Research Statistics
Russian-origin ACTH(4-7) analog approved in Russia for stroke and cognitive indications. Some Eastern European and limited Western research; primarily Russian clinical data. BDNF upregulation and neuroprotection mechanisms are supported but studied mainly in Russian institutes.
Research Dossier
Overview
What is Semax and what does the research say?
Mechanism of Action
Semax has a complex, multi-target mechanism of action that distinguishes it from traditional nootropics. Unlike its parent ACTH molecule, Semax does not stimulate cortisol release, making it safe for long-term neurological use.
How It Works (Simplified)
Semax acts as a “brain fertilizer and protector” through several complementary pathways:
Rapidly increases BDNF and NGF expression (up to 8-fold within 30 minutes), supporting learning, memory, neuronal survival, and recovery from injury.
Activates dopamine and serotonin systems in striatum and frontal cortex, enhancing attention, motivation, and mood without depleting neurotransmitter stores.
Suppresses pro-inflammatory cytokines (IL-1, IL-6, TNF-alpha) and chemokines following brain injury, protecting neurons from secondary damage.
Modulates hundreds of genes involved in neurotransmission, immune response, and cell survival, producing sustained benefits through transcriptional changes.
Scientific Pathways
BDNF/NGF Neurotrophin Pathway (Neuroprotection & Cognition)
Semax (intranasal) → CNS penetration → Gene expression activation
↓
BDNF mRNA ↑ (8-fold at 30 min)
NGF mRNA ↑ (5-fold at 30 min)
↓
TrkB/TrkA receptor upregulation
↓
Enhanced neuroplasticity → Memory consolidationDopaminergic/Serotonergic Pathway (Attention & Mood)
Semax → Striatum and frontal cortex → 5-HIAA ↑ (25-180%)
→ Dopamine system modulation
↓
Improved attention, motivation, moodAnti-Inflammatory Pathway (Neuroprotection)
Brain injury → Inflammatory cascade → Semax intervention
↓
IL-1a, IL-1b, IL-6, TNF-alpha mRNA ↓
Ccl3, Cxcl2 (chemokines) ↓
↓
Reduced secondary neuronal damageImportant Limitations
- Most research originates from Russian institutions with limited Western independent replication
- Many primary studies published only in Russian, creating language barriers for verification
- Historical clinical trials may not meet current Western GLP/GCP standards
- Human pharmacokinetics and optimal dosing not fully characterized by Western standards
- No FDA or EMA regulatory pathway has been pursued
Evidence-Chained Benefits
Evidence-Chained Benefits
Research findings linked to mechanisms and clinical outcomes
What to Expect
Timeline based on observations from published studies. Individual responses may vary.
Based on preclinical and clinical data: Rapid BDNF/NGF upregulation begins within 30 minutes of intranasal administration. In stroke patients, early intervention shows greatest benefits. Dopamine and serotonin modulation observed.
In stroke rehabilitation trials, BDNF levels increased significantly and functional recovery (Barthel scores) improved over 2-4 weeks. Anti-inflammatory effects reduce secondary brain damage. Clinical trials showed improved attention and cognitive function.
Russian protocols typically use 10-14 day treatment courses. Long-term effects and optimal duration not characterized by Western standards. Some conditions may require repeated courses.
Long-term maintenance protocols not well-established. Russian clinical practice suggests periodic treatment courses rather than continuous administration. Human pharmacokinetics not fully characterized.
Research-Based Observations
This timeline reflects observations from published clinical and preclinical studies. Individual responses may vary significantly. This is not a guarantee of effects or a dosing schedule. Consult qualified healthcare providers for personalized guidance.
Quality Checklist
Visual indicators to help evaluate Semax product quality
Good Signs (6 indicators)
Warning Signs (5 indicators)
Bad Signs (6 indicators)
For Research Evaluation Only
These quality indicators are general guidelines based on typical peptide characteristics. Professional laboratory testing (HPLC, mass spectrometry) provides definitive quality verification. This checklist is for initial visual evaluation only.
Peptide Interactions
Known and theoretical interactions when combining Semax with other peptides. Based on published research and mechanistic considerations.
Selank
SynergisticComplementary Russian regulatory peptides - Semax provides nootropic/neuroprotective effects via BDNF while Selank offers anxiolysis via GABA. Common clinical combination in Russia.
Epithalon
CompatibleBoth Russian bioregulator peptides with different CNS targets - Semax for acute neuroprotection via BDNF, epithalon for cellular longevity via telomeres.
BPC-157
CompatibleBoth have neuroprotective properties - Semax via BDNF/NGF upregulation, BPC-157 via multiple CNS repair mechanisms. May have complementary neuroprotective effects.
Thymosin-Alpha-1
CompatibleSemax has immunomodulatory effects alongside nootropic actions; Ta1 is primarily immunomodulatory. Different primary mechanisms with potential immune synergy.
TB-500
CompatibleBoth promote tissue repair - Semax in CNS via neurotrophins, TB-500 systemically via actin regulation. Different primary targets.
Research Note: Interaction data is based on published literature, mechanistic understanding, and theoretical considerations. Most peptide combinations lack direct clinical study. This information is for educational purposes only and does not constitute medical advice. Always consult qualified healthcare providers.
References
Key Studies Cited
Full reference list available on request. All citations link to PubMed for verification.
Methodology Note
This dossier synthesizes available evidence from peer-reviewed literature, regulatory documents, and clinical trial registries. Evidence strength ratings follow a modified GRADE approach.
For complete methodology details, see our Methodology page.
Important Disclaimer
This dossier is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making health decisions.
Get Research Alerts
New dossiers and major study summaries delivered to your inbox. Evidence-graded, citation-backed research you can trust.
No spam. Unsubscribe anytime.
Compare Semax
Semax Calculators
Related Peptides
Alixorexton
ALKS 2680, ALKS-2680
An oral orexin receptor 2 (OX2R) agonist developed by Alkermes for narcolepsy type 1 (NT1). Phase 2 clinical trials demonstrated improvements in excessive daytime sleepiness and cataplexy with once-daily dosing. Represents a novel approach to restore orexin signaling in patients who have lost orexin-producing neurons.
Cerebrolysin
FPF-1070, N-PEP-12, Renacenz
A porcine brain-derived peptide mixture approved in over 50 countries (Austria, Russia, China, Germany) for stroke, dementia, and traumatic brain injury. Contains neurotrophic peptide fragments mimicking BDNF, GDNF, NGF, and CNTF. NOT FDA-approved despite decades of international use. Mixed Phase 3 results but positive meta-analyses and widespread clinical adoption in Europe, Asia, and Latin America.
Cerluten
Brain cytamin, Cerebral peptides, A-5 brain peptides
A cytamin-class peptide supplement derived from brain tissue, part of the Russian bioregulator framework. Marketed as an oral supplement for cognitive support and neuroprotection. Contains peptide complexes rather than defined sequences. No Western clinical validation.
Cortexin
Cortexinum, Polypeptide brain extract, Bovine brain cortex polypeptides
A Russian neuropeptide complex derived from porcine or bovine cerebral cortex, approved in Russia and CIS countries for neurological conditions. Contains low molecular weight polypeptides (1,000-10,000 Da) with proposed neurotrophic and neuroprotective properties. NOT approved by FDA, EMA, or other Western regulatory agencies. Evidence comes primarily from Russian studies with limited Western validation.
Dihexa
PNB-0408, N-hexanoic-Tyr-Ile-(6) aminohexanoic amide
An angiotensin IV analog developed by Washington State University researchers, claimed to enhance cognition through HGF/c-Met signaling. Gained attention for extreme potency claims (10 million times more potent than BDNF), but evidence is limited to rodent studies from a single research group with no human clinical trials. Sold as a research chemical with unknown safety profile.
DSIP
Delta Sleep Inducing Peptide, Delta Sleep-Inducing Peptide, WAGGDASGE
A nonapeptide discovered in 1977 that was initially thought to induce delta wave sleep. Research has shown broader neuromodulatory effects including stress-protection and analgesia, though its role as an endogenous sleep factor remains controversial.